---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Taysha Gene Therapies, Nonproprietary name and development code, Nonproprietary name: WHO proposed International Nonproprietary Name and substance description, Therapeutic class: self-complementary AAV9 gene transfer therapy, and 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Taysha Gene Therapies

> “Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.”
> “Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.1-2"></a>

### Nonproprietary name and development code

> “LONIMECGENE RENPARVOVEC [USAN]”
> “lonimecgene renparvovec [INN]”
> “TSHA-102”
> “2856375-48-7”

Source: [FDA UNII NVK87P6NXW](https://precision.fda.gov/uniisearch/srs/unii/NVK87P6NXW)

<a id="topic-2.1.2.1-3"></a>

### Nonproprietary name: WHO proposed International Nonproprietary Name and substance description

> “lonimecgene renparvovec”
> “gene therapy (Rett syndrome)”

Source: [WHO Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)

<a id="topic-2.1.2.1-4"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-5"></a>

### Therapeutic class: self-complementary AAV9 gene transfer therapy

> “TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.”
> “Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.1-6"></a>

### Licensing: Abeona Rett Agreement

> “In October 2020, we entered into a license agreement, or the Abeona Rett Agreement, with Abeona Therapeutics Inc., or Abeona, pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill, the University of Edinburgh and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy and the use of related transgenes for Rett syndrome.”
> “We are obligated to pay Abeona up to $26.5 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed product and high single-digit royalties on net sales of licensed products.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.1-7"></a>

### Licensing: patent rights in-licensed for TSHA-102

> “We in-license from The Board of Regents of The University of Texas System four pending patent applications worldwide directed to a minigene encoding MECP2 packaged into an AAV vector, and methods of using that vector to treat Rett syndrome.”
> “Under the Abeona Rett Agreement, we also sub-license from the University of Edinburgh and the University of Glasgow 10 pending patent applications worldwide directed to MECP2 expression cassettes for gene therapy.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.1-8"></a>

### Rights to the product: Astellas option expired in October 2025

> “In October 2025, the Option Agreement expired without Astellas exercising the GAN Option or Rett Option. Pursuant to the expiration of the Option Agreement, we regained full and unencumbered global rights to TSHA-102.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

> “Following the expiration of the Option Agreement, Taysha now holds unencumbered rights to the TSHA-102 program.”

Source: [Taysha Gene Therapies full rights announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/d35488dex991.htm)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
